Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The projected business potential is around US$ 1 million in the first year
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The acquired ANDAs represent a market opportunity of about US$ 38 million in the USA
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
_256_384.jpg)
Marksans Pharma gets USFDA nod for acid reflux drug
Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S
Reinforcing commitment to ethical and sustainable growth
Subscribe To Our Newsletter & Stay Updated
